EA014852B1 - Система контролируемой доставки - Google Patents
Система контролируемой доставки Download PDFInfo
- Publication number
- EA014852B1 EA014852B1 EA200700653A EA200700653A EA014852B1 EA 014852 B1 EA014852 B1 EA 014852B1 EA 200700653 A EA200700653 A EA 200700653A EA 200700653 A EA200700653 A EA 200700653A EA 014852 B1 EA014852 B1 EA 014852B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- composition
- bupivacaine
- anesthetic
- administration
- pain
- Prior art date
Links
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229960003150 bupivacaine Drugs 0.000 claims abstract description 62
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000002904 solvent Substances 0.000 claims abstract description 27
- 235000019445 benzyl alcohol Nutrition 0.000 claims abstract description 18
- 238000002690 local anesthesia Methods 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 claims abstract description 11
- 239000001797 sucrose acetate isobutyrate Substances 0.000 claims abstract description 10
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 156
- 206010052428 Wound Diseases 0.000 claims description 35
- 208000027418 Wounds and injury Diseases 0.000 claims description 35
- 230000007774 longterm Effects 0.000 claims description 12
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 208000002847 Surgical Wound Diseases 0.000 claims description 8
- 206010019909 Hernia Diseases 0.000 claims description 3
- 208000004550 Postoperative Pain Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 238000007486 appendectomy Methods 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 46
- 230000036407 pain Effects 0.000 description 46
- 230000003444 anaesthetic effect Effects 0.000 description 45
- 238000012360 testing method Methods 0.000 description 41
- 229920000642 polymer Polymers 0.000 description 35
- 238000000034 method Methods 0.000 description 27
- 239000000654 additive Substances 0.000 description 24
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 239000003193 general anesthetic agent Substances 0.000 description 16
- 229940035676 analgesics Drugs 0.000 description 14
- 239000000730 antalgic agent Substances 0.000 description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 229920002988 biodegradable polymer Polymers 0.000 description 12
- 239000004621 biodegradable polymer Substances 0.000 description 12
- 239000000835 fiber Substances 0.000 description 12
- 239000007943 implant Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 239000012876 carrier material Substances 0.000 description 10
- 239000003589 local anesthetic agent Substances 0.000 description 10
- 238000013270 controlled release Methods 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- -1 glidants Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 230000003285 pharmacodynamic effect Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 229920000747 poly(lactic acid) Polymers 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000010254 subcutaneous injection Methods 0.000 description 6
- 239000007929 subcutaneous injection Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 229920000954 Polyglycolide Polymers 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229920002732 Polyanhydride Polymers 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001710 Polyorthoester Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229920001169 thermoplastic Polymers 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 230000001755 vocal effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229960001050 bupivacaine hydrochloride Drugs 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 229940124583 pain medication Drugs 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002620 polyvinyl fluoride Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JCQBWMAWTUBARI-UHFFFAOYSA-N tert-butyl 3-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C=C)C1 JCQBWMAWTUBARI-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- HKQOBOMRSSHSTC-UHFFFAOYSA-N cellulose acetate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 HKQOBOMRSSHSTC-UHFFFAOYSA-N 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920001855 polyketal Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Selective Calling Equipment (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Detergent Compositions (AREA)
- Optical Communication System (AREA)
- Amplifiers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61079704P | 2004-09-17 | 2004-09-17 | |
| US69139505P | 2005-06-17 | 2005-06-17 | |
| PCT/US2005/032863 WO2006033948A2 (en) | 2004-09-17 | 2005-09-15 | Sustained local anesthetic composition containing preferably a sugar ester such as saib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200700653A1 EA200700653A1 (ru) | 2007-10-26 |
| EA014852B1 true EA014852B1 (ru) | 2011-02-28 |
Family
ID=35949130
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200700653A EA014852B1 (ru) | 2004-09-17 | 2005-09-15 | Система контролируемой доставки |
| EA201001885A EA201001885A1 (ru) | 2004-09-17 | 2005-09-15 | Система контролируемой доставки |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201001885A EA201001885A1 (ru) | 2004-09-17 | 2005-09-15 | Система контролируемой доставки |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US8753665B2 (enExample) |
| EP (4) | EP1809329B1 (enExample) |
| JP (2) | JP5285275B2 (enExample) |
| KR (2) | KR101492361B1 (enExample) |
| AT (1) | ATE537844T1 (enExample) |
| AU (1) | AU2005287175B2 (enExample) |
| BR (1) | BRPI0515372B8 (enExample) |
| CA (1) | CA2581287C (enExample) |
| CY (2) | CY1112625T1 (enExample) |
| DK (3) | DK2767292T3 (enExample) |
| EA (2) | EA014852B1 (enExample) |
| ES (3) | ES2378671T3 (enExample) |
| GE (1) | GEP20094831B (enExample) |
| HR (1) | HRP20120254T1 (enExample) |
| HU (1) | HUE032040T2 (enExample) |
| IL (1) | IL181474A (enExample) |
| LT (1) | LT2767292T (enExample) |
| MX (1) | MX2007002962A (enExample) |
| NO (1) | NO342596B1 (enExample) |
| NZ (1) | NZ553369A (enExample) |
| PL (2) | PL2415484T3 (enExample) |
| PT (3) | PT1809329E (enExample) |
| RS (1) | RS52198B (enExample) |
| SI (2) | SI2415484T1 (enExample) |
| WO (1) | WO2006033948A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833543B2 (en) * | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
| US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| DK2767292T3 (en) | 2004-09-17 | 2016-12-19 | Durect Corp | RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB |
| CN101060831B (zh) * | 2004-10-01 | 2010-06-23 | 拉姆斯科股份有限公司 | 可方便植入的缓释药物组合物 |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| EP2484347A1 (en) | 2006-11-03 | 2012-08-08 | Durect Corporation | Transdermal delivery systems comprising bupivacaine |
| PT3085363T (pt) * | 2007-03-28 | 2019-05-16 | Innocoll Pharm Ltd | Dispositivo de administração de fármacos para proporcionar analgesia local, anestesia local ou bloqueio nervoso |
| WO2009100222A1 (en) * | 2008-02-08 | 2009-08-13 | Qps Llc | Non-polymeric compositions for controlled drug delivery |
| US20100143437A1 (en) * | 2008-12-09 | 2010-06-10 | Morris Edward J | Implantable analgesic |
| WO2010132673A1 (en) | 2009-05-13 | 2010-11-18 | Keraplast Technologies, Ltd. | Biopolymer materials |
| WO2012074883A1 (en) * | 2010-11-24 | 2012-06-07 | Durect Corporation | Biodegradable drug delivery composition |
| ES2985957T3 (es) * | 2012-05-16 | 2024-11-07 | Orexa B V | Anestésicos locales para facilitar la ingesta de alimentos y retención de alimentos |
| MX352907B (es) | 2013-03-15 | 2017-12-13 | Heron Therapeutics Inc | Composiciones de un poliortoéster y un solvente aprótico. |
| CA2913100C (en) * | 2013-05-24 | 2021-10-26 | Danmarks Tekniske Universitet | Gel formulations for guiding radiotherapy |
| CA2931547A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| WO2015123734A1 (en) * | 2014-02-21 | 2015-08-27 | The University Of Sydney | Liquid carrier materials |
| US11083730B2 (en) | 2014-04-21 | 2021-08-10 | Heron Therapeutics, Inc. | Long-acting polymeric delivery systems |
| BR112016024665B1 (pt) | 2014-04-21 | 2023-04-11 | Heron Therapeutics, Inc | Composição, composição semissólida e seu uso |
| GB201505527D0 (en) | 2015-03-31 | 2015-05-13 | Jmedtech Pte Ltd | Composition |
| KR20170025011A (ko) | 2015-08-27 | 2017-03-08 | 고려대학교 산학협력단 | 통증완화약물의 지속성 방출을 위한 약학적 조성물 및 그 투여를 위한 투여 장치 |
| JP2019514976A (ja) * | 2016-05-05 | 2019-06-06 | リクイディア・テクノロジーズ・インコーポレーテッド | 負荷と放出が正確に制御された術後疼痛用粒子 |
| US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| BR112018077259A2 (pt) | 2016-06-30 | 2019-06-18 | Durect Corporation | formulações depot |
| KR102442753B1 (ko) * | 2016-12-26 | 2022-09-16 | 셀릭스 바이오 프라이빗 리미티드 | 만성 통증 치료를 위한 화합물 |
| KR102248445B1 (ko) * | 2017-03-27 | 2021-05-04 | 프루티 홀딩스 리미티드 | 불용성 착물 또는 이의 용매화물, 약제학적 조성물 및 이의 용도 |
| JP2020536955A (ja) | 2017-10-06 | 2020-12-17 | ファウンドリー セラピューティクス， インコーポレイテッド | 治療剤の制御放出のための埋込み可能なデポー |
| RU2674025C1 (ru) * | 2017-10-25 | 2018-12-04 | Общество с ограниченной ответственностью "Научно-производственная фирма "ЭЛЕСТ" (ООО "НПФ "ЭЛЕСТ") | Лекарственное средство на основе порфиринового фотосенсибилизатора копропорфирина для лечения рака кожи методом фотодинамической терапии |
| CN111655303A (zh) | 2018-01-08 | 2020-09-11 | 铸造疗法股份有限公司 | 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法 |
| CN112367980A (zh) | 2018-05-12 | 2021-02-12 | 铸造疗法股份有限公司 | 用于控制释放治疗剂的可植入贮库 |
| CN112867484A (zh) | 2018-08-28 | 2021-05-28 | 铸造疗法股份有限公司 | 聚合物植入物 |
| CN115605182A (zh) * | 2020-01-06 | 2023-01-13 | 帕西拉制药股份有限公司（Us） | 用缓释脂质体麻醉组合物治疗剖宫产手术相关疼痛 |
| CN115515581A (zh) | 2020-01-10 | 2022-12-23 | 帕西拉制药股份有限公司 | 通过给予缓释脂质体麻醉组合物治疗疼痛 |
| WO2021141963A1 (en) | 2020-01-10 | 2021-07-15 | Pacira Pharmaceuticals, Inc. | Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions |
| CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
| JP7642248B2 (ja) * | 2020-02-25 | 2025-03-10 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 共融体に基づく麻酔組成物およびその適用 |
| WO2022150708A1 (en) | 2021-01-11 | 2022-07-14 | Pacira Pharmaceuticals, Inc. | Treatment of hip pain with sustained-release liposomal anesthetic compositions |
| CN116940358A (zh) | 2021-01-12 | 2023-10-24 | 度勒科特公司 | 持续释放药物递送系统和有关的方法 |
| CN115068414B (zh) * | 2021-03-16 | 2023-07-21 | 湖南慧泽生物医药科技有限公司 | 供注射用罗哌卡因长效溶液制剂及其制备方法 |
| CN117320696A (zh) | 2021-03-19 | 2023-12-29 | 帕西拉制药股份有限公司 | 通过给予缓释脂质体麻醉组合物治疗儿科患者的疼痛 |
| CN115414324A (zh) * | 2021-05-31 | 2022-12-02 | 中国科学院过程工程研究所 | 一种载局部麻醉药的乳剂及其制备方法 |
| IL314565A (en) | 2022-01-28 | 2024-09-01 | Rebel Medicine Inc | Pharmaceutical preparations for pain treatment |
| US12226610B2 (en) | 2022-11-03 | 2025-02-18 | Pacira Pharmaceuticals, Inc. | Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions |
| US11918565B1 (en) | 2022-11-03 | 2024-03-05 | Pacira Pharmaceuticals, Inc. | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| RU2180557C2 (ru) * | 1998-06-26 | 2002-03-20 | Казахский Государственный национальный университет им. Аль-Фараби | Анестезирующий состав пролонгированного действия |
| US6426339B1 (en) * | 1996-09-16 | 2002-07-30 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
| WO2002058670A1 (en) * | 2001-01-25 | 2002-08-01 | Euroceltique S.A. | Local anesthetic, and method of use |
| US20040101557A1 (en) * | 1995-06-07 | 2004-05-27 | Gibson John W. | High viscosity liquid controlled delivery system and medical or surgical device |
Family Cites Families (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US556450A (en) * | 1896-03-17 | Antifriction-bearing | ||
| US2931802A (en) | 1958-04-30 | 1960-04-05 | Eastman Kodak Co | Mixed esters of glucose and sucrose |
| GB1088992A (en) | 1963-09-19 | 1967-10-25 | Squibb & Sons Inc | Protective dressings |
| US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US3743398A (en) | 1971-03-22 | 1973-07-03 | Eastman Kodak Co | Motion picture projector |
| NO139560C (no) | 1972-04-29 | 1979-04-04 | Takeda Chemical Industries Ltd | Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater |
| JPS5088069A (enExample) | 1973-11-01 | 1975-07-15 | ||
| DE2438352A1 (de) | 1974-08-09 | 1976-02-26 | Hoechst Ag | Peptidcyclopropylamide mit lh-rh/fshrh-wirkung |
| DE2438350C3 (de) | 1974-08-09 | 1979-06-13 | Hoechst Ag, 6000 Frankfurt | Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| US4360019A (en) | 1979-02-28 | 1982-11-23 | Andros Incorporated | Implantable infusion device |
| JPS55154991A (en) | 1979-05-23 | 1980-12-02 | Hisamitsu Pharmaceut Co Inc | Beta-d-fructopyranoside derivative |
| NZ194405A (en) | 1979-08-02 | 1982-05-25 | Dut Pty Ltd | Producing liquid hydrocarbon streams by hydrogenation of fossil-based feedstock |
| US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| DE3716302C2 (de) | 1987-05-15 | 1996-02-01 | Henkel Kgaa | Verbesserte resorbierbare Knochenwachse und ihre Verwendung |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| JPS59210024A (ja) | 1983-05-13 | 1984-11-28 | Taiyo Kagaku Kk | トコフエロ−ル乳化物 |
| US4725442A (en) | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
| US4622219A (en) | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
| JPS607418U (ja) | 1983-06-28 | 1985-01-19 | 株式会社デンソー | 歯付スラストワツシヤをもつ軸受装置 |
| US4891225A (en) | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4630019A (en) | 1984-09-28 | 1986-12-16 | Westinghouse Electric Corp. | Molded case circuit breaker with calibration adjusting means for a bimetal |
| US4725852A (en) | 1985-05-09 | 1988-02-16 | Burlington Industries, Inc. | Random artificially perturbed liquid apparatus and method |
| US4780320A (en) | 1986-04-29 | 1988-10-25 | Pharmetrix Corp. | Controlled release drug delivery system for the periodontal pocket |
| ATE107857T1 (de) | 1986-06-10 | 1994-07-15 | Euro Celtique Sa | Zusammensetzung mit kontrollierter freisetzung von dihydrocodein. |
| US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| IT1198449B (it) | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
| GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
| US5234520A (en) | 1987-03-20 | 1993-08-10 | Morgan Adhesives Co. | Method of making an adhesive construction |
| US5391381A (en) | 1987-06-25 | 1995-02-21 | Alza Corporation | Dispenser capable of delivering plurality of drug units |
| US4795641A (en) | 1987-08-20 | 1989-01-03 | Eastman Kodak Company | Polymer blends having reverse phase morphology for controlled delivery of bioactive agents |
| US5350741A (en) | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US4987893A (en) | 1988-10-12 | 1991-01-29 | Rochal Industries, Inc. | Conformable bandage and coating material |
| US5324520A (en) | 1988-12-19 | 1994-06-28 | Vipont Pharmaceutical, Inc. | Intragingival delivery systems for treatment of periodontal disease |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| GB8926612D0 (en) | 1989-11-24 | 1990-01-17 | Erba Farmitalia | Pharmaceutical compositions |
| IT1240643B (it) | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano |
| US5110685A (en) | 1990-05-18 | 1992-05-05 | Exxon Chemical Patents, Inc. | Low friction, abrasion resistant polymer coating |
| US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| JPH05508266A (ja) | 1991-04-03 | 1993-11-18 | イーストマン・コダック・カンパニー | ＧａＡｓをドライエッチングするための高耐久性マスク |
| JP3313124B2 (ja) | 1991-07-31 | 2002-08-12 | 森下仁丹株式会社 | 親水性物質を内容物とするシームレスカプセルおよびその製法 |
| AU669856B2 (en) | 1991-08-26 | 1996-06-27 | Abbott Laboratories | Compositions and methods for the sublingual or buccal administration of therapeutic agents |
| US5487898A (en) | 1991-08-26 | 1996-01-30 | Abbott Laboratories | Compositions and method for the sublingual or buccal administration therapeutic agents |
| IL103275A0 (en) | 1991-10-01 | 1993-02-21 | Lilly Co Eli | Injectable extended release formulations and methods |
| YU87892A (sh) | 1991-10-01 | 1995-12-04 | Eli Lilly And Company Lilly Corporate Center | Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu |
| AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| EP0609345B1 (en) | 1991-10-21 | 1999-09-22 | Peptech Limited | Biocompatible implant for the timing of ovulation in mares |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| CA2125148C (en) | 1991-12-05 | 1999-05-11 | Siva N. Raman | A carbohydrate glass matrix for the sustained release of a therapeutic agent |
| CA2125483A1 (en) | 1991-12-11 | 1993-06-24 | Mary Ann Hunter | Cetylpyridinium chloride and domiphen bromide in organic solvent |
| US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| ZA932272B (en) | 1992-03-30 | 1993-10-19 | Alza Corp | Viscous suspensions of controlled-release drug particles |
| US5922340A (en) * | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
| DE69331387T2 (de) | 1992-09-10 | 2002-08-22 | Childrens Medical Center | Biodegradierbare polymeren matrizen mit verzoegerter freisetzung von lokalanaesthetika |
| SG47043A1 (en) | 1993-01-06 | 1998-03-20 | Kinerton Ltd | Ionic molecular conjugates of biodegradeble polyesters and bioactive polypeptides |
| US5340572A (en) | 1993-02-08 | 1994-08-23 | Insite Vision Incorporated | Alkaline ophthalmic suspensions |
| DE69413955T2 (de) | 1993-03-17 | 1999-04-01 | Minnesota Mining And Mfg. Co., Saint Paul, Minn. | Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel |
| CA2156075C (en) | 1993-03-17 | 2004-06-22 | Daniel C. Duan | Aerosol formulation containing a dispersing aid |
| DK44193D0 (da) | 1993-04-20 | 1993-04-20 | Euromed I S | Saarforbinding og klaebemiddel til en saarforbinding eller lignende |
| IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| JP3257750B2 (ja) | 1993-07-20 | 2002-02-18 | エチコン・インコーポレーテツド | ε−カプロラクトンおよびラクチドの液状コポリマー |
| US5879705A (en) | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
| TW282403B (enExample) | 1993-08-26 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
| WO1995009613A1 (en) | 1993-10-04 | 1995-04-13 | Mark Chasin | Controlled release microspheres |
| WO1995017901A1 (en) | 1993-12-29 | 1995-07-06 | Matrix Pharmaceutical, Inc. | Methods and compositions for the treatment of a host with a cellular proliferative disease |
| DK1125577T3 (da) | 1994-04-08 | 2006-06-19 | Qlt Usa Inc | Væskeformige medikamentindföringspræparater |
| US5633000A (en) | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
| JP3898220B2 (ja) | 1994-09-23 | 2007-03-28 | ダーウィン・ディスカバリー・リミテッド | レボブピバカインおよびその類似体の製造に使用するラセミ化と不斉変換法 |
| US5599852A (en) | 1994-10-18 | 1997-02-04 | Ethicon, Inc. | Injectable microdispersions for soft tissue repair and augmentation |
| DK0788481T3 (da) | 1994-10-25 | 2003-12-01 | Darwin Discovery Ltd | Fremgangsmåde til fremstilling af levobupivacain og analoger deraf |
| CA2200355C (en) | 1994-10-25 | 2007-03-06 | Marianne Langston | Crystallisation of levobupivacaine and analogues thereof |
| GB9501071D0 (en) | 1995-01-18 | 1995-03-08 | Chiroscience Ltd | Racemisation |
| US6384227B2 (en) | 1995-01-18 | 2002-05-07 | Darwin Discovery Ltd. | Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents |
| DE69634277T2 (de) | 1995-06-07 | 2006-01-05 | Southern Biosystems, Inc., Birmingham | Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität |
| US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
| US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
| MX9700850A (es) | 1995-06-09 | 1997-09-30 | Euro Celtique Sa | Formulaciones y metodos para proporcionar anestesia local prolongada. |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| WO1997027840A1 (en) | 1996-02-02 | 1997-08-07 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US6245351B1 (en) | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
| WO1997049391A1 (en) | 1996-06-24 | 1997-12-31 | Euro-Celtique, S.A. | Methods for providing safe local anesthesia |
| US5869669A (en) | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
| US5747051A (en) | 1996-09-27 | 1998-05-05 | Elizabeth Arden Co., Division Of Conopco, Inc. | Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid |
| US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
| US6572880B2 (en) | 1996-10-24 | 2003-06-03 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
| PT949905E (pt) | 1996-12-20 | 2001-12-28 | Alza Corp | Composicao de gel injectavel de efeito retardado e processo para a sua preparacao |
| US6203813B1 (en) | 1997-01-13 | 2001-03-20 | Lance L. Gooberman | Pharmaceutical delivery device and method of preparation therefor |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| DE19714765A1 (de) | 1997-04-10 | 1998-10-15 | Merck Patent Gmbh | Verwendung von niedermolekularen, oligomeren Estern von alpha-Hydroxysäuren und/oder aromatischen o-Hydroxysäuren in kosmetischen Formulierungen |
| US5919473A (en) | 1997-05-12 | 1999-07-06 | Elkhoury; George F. | Methods and devices for delivering opioid analgesics to wounds via a subdermal implant |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6051558A (en) | 1997-05-28 | 2000-04-18 | Southern Biosystems, Inc. | Compositions suitable for controlled release of the hormone GnRH and its analogs |
| DK1348427T3 (da) | 1997-07-29 | 2008-06-30 | Alcon Lab Inc | Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater |
| CA2308495C (en) | 1997-11-19 | 2009-01-06 | Darwin Discovery Limited | Anaesthetic formulation |
| BR9912508A (pt) | 1998-06-29 | 2001-05-02 | Pharmaceuticals Applic Associa | Métodos e composições transdérmicas para alìvio da dor |
| US6312717B1 (en) | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
| DE19858891A1 (de) | 1998-12-19 | 2000-06-21 | Merck Patent Gmbh | Verbesserte Knochensiegel |
| US6498153B1 (en) | 1998-12-31 | 2002-12-24 | Akzo Nobel N.V. | Extended release growth promoting two component composition |
| US6291013B1 (en) | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
| IL146567A0 (en) * | 1999-06-04 | 2002-07-25 | Skyepharma Inc | Oil-core particles containing a hydrophobic core material and hydrophobic drug and method for the preparation thereof |
| AU5025300A (en) | 1999-06-18 | 2001-01-09 | Southern Biosystems, Inc. | Compositions for controlled release of the hormone gnrh and its analogs |
| EP1239835B1 (en) * | 1999-12-23 | 2013-03-20 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
| DE10190041D2 (de) | 2000-01-11 | 2002-12-05 | Roland Bodmeier | Implantate, Partikel |
| BR0002246A (pt) | 2000-04-06 | 2003-04-15 | Cristalia Prod Quimicos Farm | Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis |
| WO2001078683A2 (en) | 2000-04-19 | 2001-10-25 | Genentech, Inc. | Sustained release formulations comprising growth hormone |
| US20050042194A1 (en) | 2000-05-11 | 2005-02-24 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
| WO2002010436A2 (en) | 2000-07-28 | 2002-02-07 | The Brigham And Women's Hospital, Inc. | Prognostic classification of breast cancer |
| FR2814308B1 (fr) | 2000-09-15 | 2003-03-14 | France Telecom | Procede de gestion de l'usage d'une ligne de telecommunication et systeme de mise en oeuvre |
| BR0115382A (pt) | 2000-10-30 | 2003-09-16 | Euro Celtique Sa | Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica |
| ES2554106T3 (es) | 2001-06-21 | 2015-12-16 | Genentech, Inc. | Formulación de liberación sostenida |
| BR0206984A (pt) * | 2001-11-14 | 2004-02-03 | Alza Corp | Composições de depósito injetáveis e uso destas |
| FR2838349B1 (fr) | 2002-04-15 | 2004-06-25 | Laurence Paris | Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication |
| CA2487577C (en) | 2002-05-31 | 2014-11-18 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of buprenorphine |
| US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| US20040109893A1 (en) | 2002-06-25 | 2004-06-10 | Guohua Chen | Sustained release dosage forms of anesthetics for pain management |
| JP4417039B2 (ja) | 2002-06-28 | 2010-02-17 | 太陽化学株式会社 | 水中油滴型乳化組成物 |
| JP4712380B2 (ja) * | 2002-07-26 | 2011-06-29 | 三笠製薬株式会社 | 外用剤 |
| JP2006514923A (ja) | 2002-10-25 | 2006-05-18 | ファイザー・プロダクツ・インク | 注射可能な新規なデポ製剤 |
| AU2003267763A1 (en) | 2002-10-25 | 2004-05-13 | Pfizer Products Inc. | Depot formulations of arylheterocyclic active agents in the form of a suspension |
| CN101797221B (zh) | 2002-12-13 | 2013-06-12 | 杜雷科特公司 | 包含高粘度液体载体材料的口服递药系统 |
| KR20050088196A (ko) | 2002-12-19 | 2005-09-02 | 알자 코포레이션 | 안정한 비수성 단일 상 겔 및 이식가능한 장치로부터전달하기 위한 이의 제형 |
| DE10312346A1 (de) | 2003-03-20 | 2004-09-30 | Bayer Healthcare Ag | Kontrolliertes Freisetzungssystem |
| DE10322469A1 (de) | 2003-05-19 | 2004-12-16 | Bayer Healthcare Ag | Heterocyclische Verbindungen |
| WO2005048742A1 (en) | 2003-11-14 | 2005-06-02 | Eastman Chemical Company | Sucrose acetate isobutyrate formulation |
| US20050106304A1 (en) | 2003-11-14 | 2005-05-19 | Cook Phillip M. | Sucrose acetate isobutyrate formulation |
| US20050232876A1 (en) | 2004-04-19 | 2005-10-20 | Robin Lynn Minga | Skin care compositions |
| US20080023261A1 (en) | 2004-05-14 | 2008-01-31 | Yanmar Co., Ltd. | Noise Proof Structure of Cabin |
| US20050266087A1 (en) | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
| DK2767292T3 (en) | 2004-09-17 | 2016-12-19 | Durect Corp | RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB |
| EP2361630A1 (en) | 2005-02-03 | 2011-08-31 | Intarcia Therapeutics, Inc | Implantable drug delivery device comprising particles and an osmotic pump |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| JP5194273B2 (ja) | 2007-09-20 | 2013-05-08 | 三菱電機株式会社 | 半導体装置 |
| SE531980C2 (sv) | 2008-01-17 | 2009-09-22 | Avtech Sweden Ab | Flygstyrningsförfarande samt datorprogram och datorprogramprodukt för att genomföra förfarandet |
-
2005
- 2005-09-15 DK DK14167954.8T patent/DK2767292T3/en active
- 2005-09-15 EA EA200700653A patent/EA014852B1/ru not_active IP Right Cessation
- 2005-09-15 NZ NZ553369A patent/NZ553369A/en not_active IP Right Cessation
- 2005-09-15 AU AU2005287175A patent/AU2005287175B2/en not_active Ceased
- 2005-09-15 BR BRPI0515372A patent/BRPI0515372B8/pt not_active IP Right Cessation
- 2005-09-15 DK DK05812735.8T patent/DK1809329T3/da active
- 2005-09-15 SI SI200531885T patent/SI2415484T1/sl unknown
- 2005-09-15 ES ES05812735T patent/ES2378671T3/es not_active Expired - Lifetime
- 2005-09-15 CA CA2581287A patent/CA2581287C/en not_active Expired - Lifetime
- 2005-09-15 SI SI200532112A patent/SI2767292T1/sl unknown
- 2005-09-15 GE GEAP20059991A patent/GEP20094831B/en unknown
- 2005-09-15 EP EP05812735A patent/EP1809329B1/en not_active Expired - Lifetime
- 2005-09-15 HU HUE14167954A patent/HUE032040T2/en unknown
- 2005-09-15 LT LTEP14167954.8T patent/LT2767292T/lt unknown
- 2005-09-15 JP JP2007532447A patent/JP5285275B2/ja not_active Expired - Fee Related
- 2005-09-15 HR HR20120254T patent/HRP20120254T1/hr unknown
- 2005-09-15 US US11/663,125 patent/US8753665B2/en active Active
- 2005-09-15 DK DK11187311T patent/DK2415484T3/da active
- 2005-09-15 KR KR1020137031550A patent/KR101492361B1/ko not_active Expired - Fee Related
- 2005-09-15 MX MX2007002962A patent/MX2007002962A/es active IP Right Grant
- 2005-09-15 EP EP14167954.8A patent/EP2767292B1/en not_active Expired - Lifetime
- 2005-09-15 PL PL11187311T patent/PL2415484T3/pl unknown
- 2005-09-15 PT PT05812735T patent/PT1809329E/pt unknown
- 2005-09-15 RS RS20120121A patent/RS52198B/sr unknown
- 2005-09-15 EA EA201001885A patent/EA201001885A1/ru unknown
- 2005-09-15 EP EP20110187311 patent/EP2415484B1/en not_active Expired - Lifetime
- 2005-09-15 PT PT11187311T patent/PT2415484E/pt unknown
- 2005-09-15 AT AT05812735T patent/ATE537844T1/de active
- 2005-09-15 PL PL05812735T patent/PL1809329T3/pl unknown
- 2005-09-15 EP EP16178709.8A patent/EP3103477A1/en not_active Withdrawn
- 2005-09-15 ES ES14167954.8T patent/ES2602273T3/es not_active Expired - Lifetime
- 2005-09-15 KR KR1020077008645A patent/KR101351771B1/ko not_active Expired - Fee Related
- 2005-09-15 WO PCT/US2005/032863 patent/WO2006033948A2/en not_active Ceased
- 2005-09-15 ES ES11187311.3T patent/ES2496765T3/es not_active Expired - Lifetime
- 2005-09-15 PT PT141679548T patent/PT2767292T/pt unknown
-
2007
- 2007-02-21 IL IL181474A patent/IL181474A/en active IP Right Grant
- 2007-04-16 NO NO20071914A patent/NO342596B1/no not_active IP Right Cessation
- 2007-07-31 US US11/888,648 patent/US8153661B2/en not_active Expired - Lifetime
- 2007-07-31 US US11/888,658 patent/US8153149B2/en active Active
-
2008
- 2008-09-30 JP JP2008252115A patent/JP5285374B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-12 CY CY20121100253T patent/CY1112625T1/el unknown
-
2013
- 2013-03-07 US US13/789,416 patent/US8846072B2/en not_active Expired - Lifetime
-
2014
- 2014-08-20 US US14/464,624 patent/US20150111924A1/en not_active Abandoned
-
2016
- 2016-01-25 US US15/005,937 patent/US20160235726A1/en not_active Abandoned
- 2016-11-24 CY CY20161101218T patent/CY1118360T1/el unknown
-
2017
- 2017-01-09 US US15/402,011 patent/US20170216267A1/en not_active Abandoned
-
2018
- 2018-01-12 US US15/870,745 patent/US20180256553A1/en not_active Abandoned
-
2019
- 2019-02-20 US US16/281,026 patent/US20190231762A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US20040101557A1 (en) * | 1995-06-07 | 2004-05-27 | Gibson John W. | High viscosity liquid controlled delivery system and medical or surgical device |
| US6426339B1 (en) * | 1996-09-16 | 2002-07-30 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
| RU2180557C2 (ru) * | 1998-06-26 | 2002-03-20 | Казахский Государственный национальный университет им. Аль-Фараби | Анестезирующий состав пролонгированного действия |
| WO2002058670A1 (en) * | 2001-01-25 | 2002-08-01 | Euroceltique S.A. | Local anesthetic, and method of use |
| US20030152637A1 (en) * | 2001-01-25 | 2003-08-14 | Mark Chasin | Local anesthetic, and method of use |
Non-Patent Citations (2)
| Title |
|---|
| "IDdb news focus" CURRENT DRUG DISCOVERY 2004 UNITED KINGDOM, no. NOV., 2004, pages 7-10, XP001208384 ISSN: 1472-7463 page 8, paragraph 1 * |
| JOHNSON R. M. ET AL.: "Applications of continuous site-directed drug delivery "PROCEEDINGS OF THE WESTERN PHARMACOLOGY SOCIETY 2002 UNITED STATES, vol. 45, 2002, pages 219-222, XP009063147 ISSN: 0083-8969 the whole document page 222, column 1, lines 1-7,20-31,45-53 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA014852B1 (ru) | Система контролируемой доставки | |
| AU2012201226B2 (en) | Sustained local anesthetic composition containing preferably a sugar ester such as SAIB | |
| CN101035562B (zh) | 优选含有如蔗糖醋酸异丁酸酯等糖酯的持续局部麻醉组合物 | |
| AU2017228714A1 (en) | Sustained local anesthetic composition containing preferably a sugar ester such as SAIB | |
| HK1201437B (en) | Sustained local anesthetic composition containing saib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ BY KZ RU |